Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as costs rose.

Hims & Hers said the U.S. FDA's decision that the shortage of Novo Nordisk's weight-loss and diabetes drugs had been resolved ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...

Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...

Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December ...

Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

Hims&Hers Health Inc (NYSE:HIMS) reported weaker-than-expected fourth-quarter earnings that overshadowed the telehealth company's revenue that topped Wall Street estimates.

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...